An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.
Amides of salicylic acid.
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.
Services providing pharmaceutic and therapeutic drug information and consultation.
Printed publications usually having a format with no binding and no cover and having fewer than some set number of pages. They are often devoted to a single subject.
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
The teaching or training of patients concerning their own health needs.
Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
Computer-based systems for input, storage, display, retrieval, and printing of information contained in a patient's medical record.

The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. (1/16)

1. The pharmacology of the acute hyperthermia that follows 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') administration to rats has been investigated. 2. MDMA (12.5 mg kg(-1) i.p.) produced acute hyperthermia (measured rectally). The tail skin temperature did not increase, suggesting that MDMA may impair heat dissipation. 3. Pretreatment with the 5-HT(1/2) antagonist methysergide (10 mg kg(-1)), the 5-HT(2A) antagonist MDL 100,907 (0.1 mg kg(-1)) or the 5-HT(2C) antagonist SB 242084 (3 mg kg(-1)) failed to alter the hyperthermia. The 5-HT(2) antagonist ritanserin (1 mg kg(-1)) was without effect, but MDL 11,939 (5 mg kg(-1)) blocked the hyperthermia, possibly because of activity at non-serotonergic receptors. 4. The 5-HT uptake inhibitor zimeldine (10 mg kg(-1)) had no effect on MDMA-induced hyperthermia. The uptake inhibitor fluoxetine (10 mg kg(-1)) markedly attenuated the MDMA-induced increase in hippocampal extracellular 5-HT, also without altering hyperthermia. 5. The dopamine D(2) antagonist remoxipride (10 mg kg(-1)) did not alter MDMA-induced hyperthermia, but the D(1) antagonist SCH 23390 (0.3 - 2.0 mg kg(-1)) dose-dependently antagonized it. 6. The dopamine uptake inhibitor GBR 12909 (10 mg kg(-1)) did not alter the hyperthermic response and microdialysis demonstrated that it did not inhibit MDMA-induced striatal dopamine release. 7. These results demonstrate that in vivo MDMA-induced 5-HT release is inhibited by 5-HT uptake inhibitors, but MDMA-induced dopamine release may not be altered by a dopamine uptake inhibitor. 8. It is suggested that MDMA-induced hyperthermia results not from MDMA-induced 5-HT release, but rather from the increased release of dopamine that acts at D(1) receptors. This has implications for the clinical treatment of MDMA-induced hyperthermia.  (+info)

Regulation of depotentiation and long-term potentiation in the dentate gyrus of freely moving rats by dopamine D2-like receptors. (2/16)

Dopamine receptors are significantly involved in hippocampus-based cognitive processes. Whereas the involvement of D1-like receptors in hippocampal plasticity has been described, the role of D2-like receptors remains to be clarified. Therefore, we investigated the contribution of D2-like receptors to synaptic transmission, long-term potentiation (LTP) and depotentiation in the dentate gyrus of freely moving rats. Male Wistar rats underwent chronic implantation of a recording electrode in the granule cell layer, a stimulating electrode in the medial perforant path and a cannula in the ipsilateral cerebral ventricle (to enable drug administration). The D2-like receptor agonists quinpirole and noraporphine dose-dependently inhibited basal synaptic transmission. Agonist priming of D2-like receptors with a drug concentration which had no effect on synaptic transmission inhibited depotentiation but did not affect LTP. The agonist effects on depotentiation were prevented by the D2-like antagonist remoxipride. Remoxipride itself did not influence basal synaptic transmission or depotentiation. Interestingly, 'weak' LTP (<4 h) but not 'strong' LTP (>24 h) was inhibited by prior application of remoxipride. These results suggest a specific role for dopamine D2-like receptors in the regulation of both depotentiation and LTP in vivo and offer an important and novel insight as to the involvement of these receptors in processes related to learning and memory.  (+info)

A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. (3/16)

Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride. Remoxipride was evaluated in a low (30 to 90 mg), medium (120 to 240 mg) and a high (300 to 600 mg) dose range and compared with a haloperidol (15 to 45 mg), which was administered to a similar group of patients. The results support the antipsychotic effect of remoxipride, with maximum efficacy occurring at daily doses between 120 mg and 600 mg. Side-effects were more frequent at doses of remoxipride over 300 mg. In all groups, remoxipride caused consistently fewer extrapyramidal side-effects than haloperidol. The antipsychotic effect of remoxipride may be derived from specific blockade of dopamine D2 receptors in the mesolimbic tract. The findings also suggest that remoxipride may have a therapeutic effect on negative symptoms of schizophrenia.  (+info)

Development of behavioral sensitization to the cocaine-like fungicide triadimefon is prevented by AMPA, NMDa, DA D1 but not DA D2 receptor antagonists. (4/16)

Triadimefon (TDF) is a triazole fungicide that blocks the reuptake of dopamine (DA) and leads to increased locomotor activity levels in mice and rats, effects similar to those of indirect DA agonists such as cocaine. We recently found in mice that intermittent TDF administration led to robust locomotor sensitization, a phenomenon reflecting neuronal plasticity, following challenge with the same TDF dose after a 2-week withdrawal period. The current study sought to determine whether antagonists to DA D1-like receptors (SCH 23390; SCH), DA D2-like receptors (remoxipride; Rem), ionotropic glutamate n-methyl-d-aspartate (NMDA) receptors (CPP), or ionotropic glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (NBQX) could prevent the development of TDF behavioral sensitization, therefore indicating their mechanistic involvement in TDF sensitization. Mice were treated with either vehicle, SCH (0.015 mg/kg), remoxipride (Rem, 0.3 mg/kg), CPP (2.5 mg/kg) or NBQX (10.0 mg/kg), followed 30 min later by vehicle or 75 mg/kg TDF (TDF), twice a week for 7 weeks, with locomotor activity measured post-dosing once a week. After a 2-week withdrawal period, mice were challenged with 75 mg/kg TDF or vehicle, to test for the presence of behavioral sensitization. Pretreatment with SCH, CPP, or NBQX, but not Rem, blocked the development of behavioral sensitization to TDF specifically for vertical activity. Antagonists that blocked TDF vertical sensitization also attenuated the increase in extracellular DA turnover (homovanillic acid [HVA]/DA) normally associated with this behavioral response. Therefore, DA D1, NMDA and AMPA receptors appear to be necessary for the development of behavioral sensitization to TDF. As such, TDF may be considered an environmental risk factor for behavioral dysfunctions linked to glutamatergic and dopaminergic systems.  (+info)

Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. (5/16)

BACKGROUND: Several clinical studies suggested that antipsychotic-based medications could ameliorate cognitive functions impaired in certain schizophrenic patients. Accordingly, we investigated the effects of various dopaminergic receptor antagonists--including atypical antipsychotics that are prescribed for the treatment of schizophrenia--in a model of toxicity using cultured hippocampal neurons, the hippocampus being a region of particular relevance to cognition. RESULTS: Hippocampal cell death induced by deprivation of growth medium constituents was strongly blocked by drugs including antipsychotics (10(-10)-10(-6) M) that display nM affinities for D2 and/or D4 receptors (clozapine, haloperidol, (+/-)-sulpiride, domperidone, clozapine, risperidone, chlorpromazine, (+)-butaclamol and L-741,742). These effects were shared by some caspases inhibitors and were not accompanied by inhibition of reactive oxygen species. In contrast, (-)-raclopride and remoxipride, two drugs that preferentially bind D2 over D4 receptors were ineffective, as well as the selective D3 receptor antagonist U 99194. Interestingly, (-)-raclopride (10(-6) M) was able to block the neuroprotective effect of the atypical antipsychotic clozapine (10(-6) M). CONCLUSION: Taken together, these data suggest that D2-like receptors, particularly the D4 subtype, mediate the neuroprotective effects of antipsychotic drugs possibly through a ROS-independent, caspase-dependent mechanism.  (+info)

Remoxipride: pharmacokinetics and effect on plasma prolactin. (6/16)

1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in 15 healthy subjects after an intravenous infusion of 50 mg, an intramuscular injection of 100 mg and after administration of two immediate release capsules (A and B), each of 100 mg, in a cross-over study. The effect of the different remoxipride formulations on plasma prolactin concentrations was also studied. 2. The volume of distribution of remoxipride was 0.65 +/- 0.11 kg-1 (mean +/- s.d.). Total plasma clearance was 119 +/- 39 ml min-1, of which 31 +/- 13 ml min-1 was due to renal clearance. The absolute bioavailability after the i.m. and oral formulations was greater than 90%, indicating a small extent of first-pass metabolism. The mean elimination half-life was 4.8 +/- 1.4 h. The unbound fraction of remoxipride and the blood/plasma ratio were 0.19 +/- 0.03 and 0.64 +/- 0.06, respectively. 3. The transient increase in plasma prolactin was similar after all four remoxipride administrations and independent of the given dose.  (+info)

New antipsychotics: classification, efficacy, and adverse effects. (7/16)

Compared to traditional neuroleptics, most of the new antipsychotics are characterized by a low extrapyramidal side effect (EPS) liability and varying antipsychotic efficacy. This topic is reviewed for four principal classes of new, established, and potential antipsychotics: (1) Antipsychotics such as sulpiride and remoxipride that block a subgroup of dopamine (DA) D2/D3 receptors produce a relatively low level of side effects, including EPS, and have an antipsychotic effect equal to or slightly weaker than traditional neuroleptics. D1 antagonists demonstrate a low level of EPS in primates and may prove to be a valuable new type of antipsychotic drug. (2) Theoretically, partial D2 agonists have the advantage of producing few or no EPS and a specific beneficial effect in negative symptoms, but as yet the expectations have not been fulfilled. (3) Nondopamine drugs such as serotonin (5HT1) agonists, 5HT2 antagonists, 5HT3 antagonists, and gamma-amino-butyric-acid-A (GABA-A) benzodiazepine agonists have anxiolytic, antidepressant, antiaggressive, and maybe antiparkinsonian effects and may play an adjunctive role in the treatment of schizophrenia. 5HT3 antagonists (e.g., ondansetron), partial benzodiazepine agonists, and partial glutamate agonists may prove to be effective antipsychotics. (4) Antipsychotics such as clozapine and risperidone, which affect D2/D3 receptors as well as 5HT, alpha 1, and/or D1 receptors appear to have the most pronounced antipsychotic effect.  (+info)

Liquid chromatographic studies on the aqueous solution conformation of substituted benzamides related to remoxipride. (8/16)

A series of disubstituted benzamides related to the sterically hindered 2,6-dimethoxybenzamide drugs, such as remoxipride, are prepared. The structure-retention relationships for these compounds are studied on hydrocarbon stationary phases in various hydroorganic mobile phases. The 2,6-dimethoxybenzamide displays a very low capacity factor under these reversed-phase conditions, suggesting that steric crowding prevents the formation of an amide-methoxy N-H...O intramolecular hydrogen bond. The corresponding 2-hydroxy-6-methoxybenzamide shows a dramatic increase in affinity for the hydrocarbon stationary phase, which is characteristic of strong intramolecular hydrogen bonding in these compounds. These results suggest that the aromatic ring--carbonyl aqueous solution conformation is almost 90 degrees in amides like remoxipride and changes to coplanarity upon demethylation of one methoxy group.  (+info)

Remoxipride is not a medication that is currently in medical use. It was a antipsychotic drug that was used in the treatment of schizophrenia, but it was withdrawn from the market in the late 1990s due to concerns about its safety. Specifically, it was found to be associated with an increased risk of a serious side effect called agranulocytosis, which is a condition characterized by a dangerously low white blood cell count.

Remoxipride belongs to a class of drugs known as benzamides, which are a type of atypical antipsychotic. These medications work by blocking the action of dopamine, a neurotransmitter in the brain that is thought to play a role in the development of psychosis. However, remoxipride has been replaced by other, safer and more effective antipsychotic medications.

It's important to note that if you are taking any medication, it is always best to consult with your healthcare provider for accurate information about its uses, side effects, and potential risks. They can provide you with the most up-to-date information and help you make informed decisions about your treatment.

Salicylamides are organic compounds that consist of a salicylic acid molecule (a type of phenolic acid) linked to an amide group. They are derivatives of salicylic acid and are known for their analgesic, anti-inflammatory, and antipyretic properties. Salicylamides have been used in various pharmaceutical and therapeutic applications, including the treatment of pain, fever, and inflammation. However, they have largely been replaced by other compounds such as acetylsalicylic acid (aspirin) due to their lower potency and potential side effects.

Haloperidol is an antipsychotic medication, which is primarily used to treat schizophrenia and symptoms of psychosis, such as delusions, hallucinations, paranoia, or disordered thought. It may also be used to manage Tourette's disorder, tics, agitation, aggression, and hyperactivity in children with developmental disorders.

Haloperidol works by blocking the action of dopamine, a neurotransmitter in the brain, which helps to regulate mood and behavior. It is available in various forms, including tablets, liquid, and injectable solutions. The medication can cause side effects such as drowsiness, restlessness, muscle stiffness, and uncontrolled movements. In rare cases, it may also lead to more serious neurological side effects.

As with any medication, haloperidol should be taken under the supervision of a healthcare provider, who will consider the individual's medical history, current medications, and other factors before prescribing it.

Antipsychotic agents are a class of medications used to manage and treat psychosis, which includes symptoms such as delusions, hallucinations, paranoia, disordered thought processes, and agitated behavior. These drugs work by blocking the action of dopamine, a neurotransmitter in the brain that is believed to play a role in the development of psychotic symptoms. Antipsychotics can be broadly divided into two categories: first-generation antipsychotics (also known as typical antipsychotics) and second-generation antipsychotics (also known as atypical antipsychotics).

First-generation antipsychotics, such as chlorpromazine, haloperidol, and fluphenazine, were developed in the 1950s and have been widely used for several decades. They are generally effective in reducing positive symptoms of psychosis (such as hallucinations and delusions) but can cause significant side effects, including extrapyramidal symptoms (EPS), such as rigidity, tremors, and involuntary movements, as well as weight gain, sedation, and orthostatic hypotension.

Second-generation antipsychotics, such as clozapine, risperidone, olanzapine, quetiapine, and aripiprazole, were developed more recently and are considered to have a more favorable side effect profile than first-generation antipsychotics. They are generally effective in reducing both positive and negative symptoms of psychosis (such as apathy, anhedonia, and social withdrawal) and cause fewer EPS. However, they can still cause significant weight gain, metabolic disturbances, and sedation.

Antipsychotic agents are used to treat various psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder with psychotic features, delusional disorder, and other conditions that involve psychosis or agitation. They can be administered orally, intramuscularly, or via long-acting injectable formulations. The choice of antipsychotic agent depends on the individual patient's needs, preferences, and response to treatment, as well as the potential for side effects. Regular monitoring of patients taking antipsychotics is essential to ensure their safety and effectiveness.

Raclopride is not a medical condition but a drug that belongs to the class of dopamine receptor antagonists. It's primarily used in research and diagnostic settings as a radioligand in positron emission tomography (PET) scans to visualize and measure the distribution and availability of dopamine D2 and D3 receptors in the brain.

In simpler terms, Raclopride is a compound that can be labeled with a radioactive isotope and then introduced into the body to track the interaction between the radioligand and specific receptors (in this case, dopamine D2 and D3 receptors) in the brain. This information can help researchers and clinicians better understand neurochemical processes and disorders related to dopamine dysfunction, such as Parkinson's disease, schizophrenia, and drug addiction.

It is important to note that Raclopride is not used as a therapeutic agent in clinical practice due to its short half-life and the potential for side effects associated with dopamine receptor blockade.

Drug Information Services (DIS) are specialized resources within healthcare systems, typically staffed by clinical pharmacists and pharmacy residents, that provide evidence-based information and analysis about medications to healthcare professionals and patients. The primary goal of DIS is to optimize medication use and improve patient outcomes through the provision of accurate, unbiased, and timely information on drug therapy.

DIS commonly provide a range of services, including:

1. Answering medication-related questions from healthcare providers, such as physicians, nurses, and other pharmacists, regarding drug interactions, dosing, adverse effects, and therapeutic alternatives.
2. Developing and maintaining formulary management systems to ensure the safe and cost-effective use of medications within a healthcare institution or system.
3. Providing patient education materials and resources on medication therapy, including proper administration techniques, potential side effects, and storage requirements.
4. Conducting ongoing literature evaluations and synthesizing evidence-based recommendations for medication use in various clinical scenarios.
5. Collaborating with healthcare teams to develop and implement guidelines, policies, and procedures related to medication management and safety.
6. Offering educational programs and resources for healthcare professionals and students to enhance their knowledge of pharmacotherapy and medication safety practices.
7. Participating in multidisciplinary committees focused on improving medication use processes, reducing medication errors, and promoting patient safety.

DIS are essential components of modern healthcare systems, as they help ensure the safe, effective, and efficient use of medications for improved patient outcomes.

I'm sorry for any confusion, but "pamphlets" is not a medical term. It refers to a small paper booklet or leaflet that can be used to provide information on various topics, including non-medical subjects. If you have any questions about medical terminology or concepts, I'd be happy to help with those!

Drug labeling refers to the information that is provided on the packaging or container of a medication, as well as any accompanying promotional materials. This information is intended to provide healthcare professionals and patients with accurate and up-to-date data about the drug's composition, intended use, dosage, side effects, contraindications, and other important details that are necessary for safe and effective use.

The labeling of prescription drugs in the United States is regulated by the Food and Drug Administration (FDA), which requires manufacturers to submit proposed labeling as part of their new drug application. The FDA reviews the labeling to ensure that it is truthful, balanced, and not misleading, and provides accurate information about the drug's risks and benefits.

The labeling of over-the-counter (OTC) drugs is also regulated by the FDA, but in this case, the agency has established a set of monographs that specify the conditions under which certain active ingredients can be used and the labeling requirements for each ingredient. Manufacturers of OTC drugs must ensure that their labeling complies with these monographs.

In addition to the information required by regulatory agencies, drug labeling may also include additional information provided by the manufacturer, such as detailed instructions for use, storage requirements, and any warnings or precautions that are necessary to ensure safe and effective use of the medication. It is important for healthcare professionals and patients to carefully review and understand all of the information provided on a drug's labeling before using the medication.

Patient education, as defined by the US National Library of Medicine's Medical Subject Headings (MeSH), is "the teaching or training of patients concerning their own health needs. It includes the patient's understanding of his or her condition and the necessary procedures for self, assisted, or professional care." This encompasses a wide range of activities and interventions aimed at helping patients and their families understand their medical conditions, treatment options, self-care skills, and overall health management. Effective patient education can lead to improved health outcomes, increased patient satisfaction, and better use of healthcare resources.

A formulary is a list of prescription drugs, both generic and brand-name, that are approved for use in a specific health plan or healthcare system. The formulary includes information on the preferred drugs within each therapeutic class, along with any restrictions or limitations on their use. Formularies are developed and maintained by a committee of healthcare professionals, including pharmacists and physicians, who evaluate the safety, efficacy, and cost-effectiveness of different medications.

The purpose of a formulary is to promote the appropriate use of medications, improve patient outcomes, and manage healthcare costs. By establishing a preferred list of drugs, health plans and healthcare systems can negotiate better prices with pharmaceutical manufacturers and ensure that patients receive high-quality, evidence-based care.

Formularies may include various types of medications, such as oral solid dosage forms, injectables, inhalants, topicals, and others. They are typically organized by therapeutic class, and each drug is assigned a tier based on its cost and clinical value. Tier 1 drugs are usually preferred generics or lower-cost brand-name medications, while Tier 2 drugs may be higher-cost brand-name medications that have no generic equivalent. Tier 3 drugs are typically specialty medications that are used to treat complex or rare conditions and are often associated with high costs.

Healthcare providers are encouraged to prescribe drugs that are listed on the formulary, as these medications have been thoroughly reviewed and deemed safe and effective for use in their patient population. However, there may be situations where a non-formulary medication is necessary to treat a particular patient's condition. In such cases, healthcare providers can request an exception or prior authorization to prescribe the non-formulary drug.

Formularies are regularly updated to reflect new drugs that come on the market, changes in clinical guidelines, and shifts in the therapeutic landscape. Health plans and healthcare systems may also modify their formularies in response to feedback from patients and providers or to address concerns about safety, efficacy, or cost.

In summary, a formulary is a comprehensive list of prescription drugs that are approved for use in a specific health plan or healthcare system. Formularies promote the appropriate use of medications, improve patient outcomes, and manage costs by encouraging the prescribing of safe and effective drugs that have been thoroughly reviewed and deemed appropriate for their patient population.

The "drug industry" is also commonly referred to as the "pharmaceutical industry." It is a segment of the healthcare sector that involves the research, development, production, and marketing of medications or drugs. This includes both prescription and over-the-counter medicines used to treat, cure, or prevent diseases and medical conditions in humans and animals.

The drug industry comprises various types of organizations, such as:

1. Research-based pharmaceutical companies: These are large corporations that focus on the research and development (R&D) of new drugs, clinical trials, obtaining regulatory approvals, manufacturing, and marketing their products globally. Examples include Pfizer, Johnson & Johnson, Roche, and Merck.

2. Generic drug manufacturers: After the patent for a brand-name drug expires, generic drug manufacturers can produce and sell a similar version of the drug at a lower cost. These companies must demonstrate that their product is bioequivalent to the brand-name drug in terms of safety, quality, and efficacy.

3. Biotechnology companies: These firms specialize in developing drugs using biotechnological methods, such as recombinant DNA technology, gene therapy, or monoclonal antibodies. Many biotech companies focus on specific therapeutic areas, like oncology, immunology, or neurology.

4. Contract research organizations (CROs): CROs provide various services to the drug industry, including clinical trial management, data analysis, regulatory affairs support, and pharmacovigilance. They work with both large pharmaceutical companies and smaller biotech firms to help streamline the drug development process.

5. Drug delivery system companies: These organizations focus on developing innovative technologies for delivering drugs more effectively and safely to patients. Examples include transdermal patches, inhalers, or long-acting injectables.

6. Wholesalers and distributors: Companies that purchase drugs from manufacturers and distribute them to pharmacies, hospitals, and other healthcare providers.

The drug industry plays a crucial role in improving public health by discovering, developing, and delivering new treatments for various diseases and medical conditions. However, it is also subject to criticism and regulation due to concerns about high drug prices, marketing practices, and the potential for conflicts of interest between industry and healthcare professionals.

A Computerized Medical Record System (CMRS) is a digital version of a patient's paper chart. It contains all of the patient's medical history from multiple providers and can be shared securely between healthcare professionals. A CMRS includes a range of data such as demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data, and radiology reports. The system facilitates the storage, retrieval, and exchange of this information in an efficient manner, and can also provide decision support, alerts, reminders, and tools for performing data analysis and creating reports. It is designed to improve the quality, safety, and efficiency of healthcare delivery by providing accurate, up-to-date, and comprehensive information about patients at the point of care.

"Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of ... Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly ... Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was ... Typical antipsychotic Benzamide Grind M, Nilsson MI, Nilsson L, Oxenstierna G, Sedvall G, Wahlén A (1989). "Remoxipride--a new ...
Remoxipride • Risperidone • Sertindole • Tiospirone • Ziprasidone • Zotepine Antiemetics: AS-8112 • Alizapride • Bromopride • ...
Remoxipride binds D2 receptors with relatively low affinity. Risperidone binds D2, D3 and D4 receptors. Risperidone not only ... Nadal R (2001). "Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist". CNS Drug Reviews. ... Nadal R (2001). "Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist". CNS Drug Reviews. ... Nadal R (2001). "Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist". CNS Drug Reviews. ...
Holm AC, Edsman I, Lundberg T, Odlind B (June 1993). "Tolerability of remoxipride in the long term treatment of schizophrenia. ...
Amisulpride Levosulpiride Nemonapride Remoxipride Sulpiride Sultopride Veralipride Anvisa (2023-03-31). "RDC Nº 784 - Listas de ...
November 1994). "The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia". ...
... remoxipride (INN) Remsed Renacidin Renagel Renamin renanolone (INN) Renedil Renese Reno Renocal Renografin Renoquid Renormax ...
... remoxipride MeSH D02. - sulpiride MeSH D02. - tiapride MeSH D02. - benzoic ... remoxipride MeSH D02.065.277.866 - sulpiride MeSH D02.065.277.882 - tiapride MeSH D02.065.463.387 - dimethylformamide MeSH ...
Renzapride Trimethobenzamide veralipride Zacopride Antipsychotics Azapride Amisulpride Levosulpiride Nemonapride Remoxipride ...
N05AH06 Clotiapine N05AH53 Olanzapine and samidorphan N05AL01 Sulpiride N05AL02 Sultopride N05AL03 Tiapride N05AL04 Remoxipride ...
"Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of ... Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly ... Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was ... Typical antipsychotic Benzamide Grind M, Nilsson MI, Nilsson L, Oxenstierna G, Sedvall G, Wahlén A (1989). "Remoxipride--a new ...
Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors. ... A dose of remoxipride is 89% recovered in the urine and 7% in the feces.4 10-40% of a dose of remoxipride is recovered in the ... The metabolism of Remoxipride can be decreased when combined with Adagrasib.. Adalimumab. The metabolism of Remoxipride can be ... The metabolism of Remoxipride can be increased when combined with Abatacept.. Abiraterone. The metabolism of Remoxipride can be ...
Detailed drug Information for Pancof HC. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.. ...
Detailed drug Information for Ketalar. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Butyrophenones (Melperone) • Indoles (Sertindole, Ziprasidone) • Benzamides (Sulpiride, Remoxipride, Amisulpride) • diazepines/ ...
Effects of Remoxipride on Psychomotor Performance, Alone and in Combination with Ethanol and Diazepam. Acta Psychiatrica ...
Remoxipride. 80125-14-0. 2-Hydroxy-1,4-naphoquinone. 83-72-7. ...
8.3.2. CYP2D6 CYP2D6 metabolizes about 25% of all drug substances, including drugs relevant to the treatment of ADHD Elvanse (AMP) Atomoxetine Nortrypti...
An open study of remoxipride in the long-term treatment of schizophrenia T Ashwood, C Hallström et al Journal of ... Remoxipride in the longterm treatment of schizophrenia A multicentre study Investigator Long-term safety study ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Remoxipride D2. D2. D2. D2.455.426.559.389.127.85.796 D2.455.426.559. ...
Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, ... Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal ...
Largely because ambient 11 photography texas of the das remoxipride total action (e.G. Behavioural theories emphasise the ...
Magnusson, O.; Mohringe, B.; Serrano, G.; Henriksson, I. 1993: Influence of remoxipride on extracellular concentrations of ...
People with serious mental illnesses are more likely to be sedentary than the general population and are consequently at high risk for chronic medical conditions associated with inactivity
Remoxipride [D02.455.426.559.389.127.085.796] * Sulpiride [D02.455.426.559.389.127.085.866] * Tiapride Hydrochloride [D02.455. ...
Mental health laws in many countries limit involuntary hospital admissions to patients who meet an obligatory dangerousness criterion for risk to themselves or others. This policy approach is in use throughout Australia, the USA, and some areas of Canada and Europe
Wiki-wiki: a wiki resource centered on human protein-protein interactions
Benzamides: Amisulpride • Remoxipride; Butyrophenones: Cinuperone • Setoperone; Benzo(iso)oxazolepiperidines: Iloperidone • ...
Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, Mishra-Kalyani PS, Helms WS, Myers CE, Skinner AM, Aungst S, Jin R, Zhao H, Xia H, Zirkelbach JF, Bi Y, Li Y, Liu J, Grimstein M, Zhang X, Woods S, Reece K, Abukhdeir AM, Ghosh S, Philip R, Tang S, Goldberg KB, Pazdur R, Beaver JA, Singh H. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clin Cancer Res. 2022 01 15; 28(2):249-254 ...
Copyright© Thomas Jefferson University. All Rights Reserved.. The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff ...
  • Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). (
  • Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia. (
  • Remoxipride is a weak selective dopamine D 2 receptor antagonist that was once used in the treatment of schizophrenia. (
  • Remoxipride is an discontinued atypical antipsychotic selective for dopamine D2 receptors. (
  • Remoxipride is an atypical antipsychotic agent that is specific for dopamine D 2 receptors. (
  • Remoxipride is an atypical antipsychotic dopamine D 2 antagonist. (
  • Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action. (
  • Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). (
  • Risperidone and remoxipride for schizophrenia. (